All In Biotech

NDA 050608 · Pfizer

Unasyn

Ampicillin Sodium, Sulbactam Sodium · Injection

Novel

Last checked: Nov 19, 2026Latest source record: Nov 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Dec 31, 1986

Approved uses

2

Original approval plus efficacy supplements

Registered trials

804

170 Phase 3, 86 recruiting

FAERS reports

1,708

1,594 serious, 337 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 10, 2026.

INDICATIONS AND USAGE UNASYN is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus , Escherichia coli , Efficacy for this organism in this organ system was studied in fewer than 10 infections. Klebsiella spp. (including K. pneumoniae ), Proteus mirabilis , Bacteroides fragilis , Enterobacter spp., and Acinetobacter calcoaceticus. NOTE: For information on use in pediatric patients (see PRECAUTIONS–Pediatric Use and CLINICAL STUDIES sections). Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli , Klebsiella spp. (including K. pneumoniae ), Bacteroides spp. (including B. fragilis ), and Enterobacter spp. Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, and Bacteroides spp. (including B. fragilis ). While UNASYN is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with UNASYN due to its ampicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to UNASYN should not require the addition of another antibacterial. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to UNASYN. Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 12, 1997 Supplement 19 · Efficacy Review
  • Dec 31, 1986 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination Review
4 products under this application
  • UNASYN · AMPICILLIN SODIUM EQ 10GM BASE/VIAL; SULBACTAM SODIUM EQ 5GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • UNASYN · AMPICILLIN SODIUM EQ 500MG BASE/VIAL; SULBACTAM SODIUM EQ 250MG BASE/VIAL · INJECTABLE, INJECTION · Discontinued
  • UNASYN · AMPICILLIN SODIUM EQ 2GM BASE/VIAL; SULBACTAM SODIUM EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • UNASYN · AMPICILLIN SODIUM EQ 1GM BASE/VIAL; SULBACTAM SODIUM EQ 500MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Ampicillin" as an intervention, any sponsor and status, largest first.

All 804 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pneumonia146
  • pyrexia129
  • dyspnoea88
  • diarrhoea80
  • pain77
  • rash75
  • drug ineffective65
  • vomiting64
  • sepsis63
  • nausea61
  • hepatic function abnormal59
  • hypotension59

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004104
2005105
200695
2007100
200890
200956
2010122
2011139
2012106
201351
201465
201579
201691
201766
201859
201950
202044
202158
202240
202368
202460
202531
202629

Recalls

1 FDA enforcement reports for this application.

  • May 29, 2020 · Class II · Terminated

    Presence of Particulate Matter: particulate matter identified after reconstitution.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Unasyn (Ampicillin Sod/Sulbactam Sod)

2024 spending

$84K

Beneficiaries

119

414 claims

Per beneficiary

$709

$20.60 per unit

View as table
YearSpending
2020$115,514
2021$139,344
2022$90,943
2023$93,239
2024$84,427

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,354 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.